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Abstract
Background: The objective of this study was to examine whether fluoxetine was superior to placebo in the acute
amelioration of depressive symptomatology in adolescents with depressive illness and a comorbid substance use
disorder.
Methods: Eligible subjects ages 12–17 years with either a current major depressive disorder (MDD) or a depressive
disorder that were also suffering from a comorbid substance-related disorder were randomized to receive either
fluoxetine or placebo in this single site, 8-week double-blind, placebo-controlled study. The primary outcome analysis
was a random effects mixed model for repeated measurements of Children's Depression Rating Scale-Revised (CDRS-
R) scores compared between treatment groups across time.
Results: An interim analysis was performed after 34 patients were randomized. Based on the results of a futility analysis,
study enrollment was halted. Twenty-nine males and 5 females were randomized to receive fluoxetine (n = 18) or
placebo (n = 16). Their mean age was 16.5 (1.1) years. Overall, patients who received fluoxetine and placebo had a
reduction in CDRS-R scores. However, there was no significant difference in mean change in CDRS-R total score in those
subjects treated with fluoxetine and those who received placebo (treatment difference = 0.19, S.E. = 0.58, F = 0.14, p =
.74). Furthermore, there was not a significant difference in rates of positive urine drug toxicology results between
treatment groups at any post-randomization visit (F = 0.22, df = 1, p = 0.65). The main limitation of this study is its modest
sample size and resulting low statistical power. Other significant limitations to this study include, but are not limited to,
the brevity of the trial, high placebo response rate, limited dose range of fluoxetine, and the inclusion of youth who met
criteria for depressive disorders other than MDD.
Conclusion: Fluoxetine was not superior to placebo in alleviating depressive symptoms or in decreasing rates of positive
drug screens in the acute treatment of adolescents with depression and a concomitant substance use disorder.
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Depression is a common condition amongst teenagers,
with prevalence estimates of approximately 3–5% [1,2].
Depression during adolescence is a serious illness that is
associated with impairments in functioning, school per-
formance, personal relationships, and suicidal behavior
[3,4]. In addition, an estimated 20%–30% of adolescents
with major depressive disorder (MDD) also suffer from at
least one comorbid substance use disorder [5]. These teen-
agers with both major depression and substance use dis-
orders are significantly more likely to suffer from more
pronounced psychosocial dysfunction, greater academic
problems, more suicidal behavior and completed suicides
than those youth without a substance use disorder [6-9].
More specifically, reported drug use has been shown to be
a predictor of subsequent suicide attempt in adolescents
[10,11] with a positive linear relationship between
number of drugs abused and likelihood of suicide attempt
[12]. Of concern is the fact that Brent et al. [13] found that
having a mood disorder and a substance use disorder may
put adolescents at a substantial increased risk for suicide.
For these reasons, safe and effective treatments for youths
who are suffering from comorbid depression and sub-
stance use disorders are needed.
Currently, fluoxetine is the only antidepressant that is
labeled by the Food and Drug Administration for use in
children and adolescents suffering from MDD [14]. Fluox-
etine has been shown to be associated with greater reduc-
tions in depressive symptomatology than placebo when
administered to depressed youths that do not suffer from
substance use disorders [15-17].
In adults, fluoxetine appears to be efficacious in the treat-
ment of adults with MDD and comorbid substance use
disorders. For example, Cornelius et al. [18] found that
adults with depression and an alcohol abuse disorder who
were treated with fluoxetine experienced greater depres-
sive symptom amelioration and a decreased consumption
of alcohol in comparison to those subjects who received
placebo.
Unfortunately, there are little data available regarding the
pharmacological treatment of depressed youths with
comorbid substance use disorders despite the prevalence
and malignancy of this combination of illnesses. A pilot
study of sertraline in 10 depressed adolescents with a sub-
stance use disorder showed a significant reduction in
depressive symptomatology and alcohol consumed in
both the sertraline-treated group and the group that
received placebo [19]. An open-label study found that
fluoxetine was effective in decreasing both depressive
symptomatology and alcohol consumption in adoles-
cents with MDD [20]. In addition, open-label treatment
with fluoxetine in substance-abusing adolescents with a
comorbid conduct disorder diagnosis who had been
abstinent for at least four weeks has been reported to
decrease depressive symptoms [21]. These preliminary
data in adolescents and placebo-controlled efficacy data
in adults suggest a possible role for the use of fluoxetine
in the treatment of depressed youth with a comorbid sub-
stance use disorder. Furthermore, fluoxetine plus cogni-
tive behavioral therapy (CBT) was found to be superior to
CBT plus placebo in adolescents with MDD, conduct dis-
order (CD), and a substance use disorder in a recently
published 16-week study [22].
The purpose of this study was to test the acute efficacy of
fluoxetine in reducing depressive symptoms, as well as the
safety and tolerability of fluoxetine in the treatment of
adolescents with a depressive disorder who also suffered
from a comorbid substance use disorder. Surprisingly, an
adequately-powered acute randomized controlled trial
where subjects receive only either an active drug or pla-
cebo for a brief period of time has yet to be published in
this population of vulnerable youths. Given the current
concerns that have been found regarding the possibility of
increased suicidality in adolescents treated with antide-
pressants [23] and the fact that these comorbid patients
appear to be at high risk for self-injurious behavior, par-
ticular attention was paid to patient safety. More specifi-
cally, as hopelessness has been reported to be strongly
associated with suicidal ideation [24,25], this specific con-
struct was monitored throughout the trial.
It was hypothesized that fluoxetine would be superior to
placebo in the amelioration of depressive symptomatol-
ogy in this patient population. Another hypothesis was
that treatment with fluoxetine would be associated with a
favorable safety and tolerability profile. As the improve-
ment of adolescents with cannabis abuse disorders may
be the result of general treatment factors [26], the use of a
placebo arm in this trial was considered scientifically
rational and ethically justifiable decision. It should also
be noted that when this study was designed, published
acute pharmacotherapy trials of depressed youths had not
included a CBT component. In addition, it was our
impression that access to CBT may be limited in commu-
nity settings. For these two reasons, CBT was not included
in this trial's design.
Methods
All procedures in this study were approved by the Univer-
sity Hospitals Case Medical Center's Institutional Review
Board for Human Investigation. Written informed con-
sent was obtained from the subject's guardian and written
assent was obtained from the subject prior to any study-
related procedures being performed.Page 2 of 13
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This was a single site, 8-week, double-blind, placebo-con-
trolled study with 2 parallel arms. Eligible youths were
randomized in approximately equal numbers to receive
either placebo or fluoxetine during the course of this
study. The pre-treatment screening assessments were com-
pleted over two visits, generally one week apart. After
receiving blinded study medication at the baseline visit,
youths returned for assessments after 4 days, and at the
end of weeks 1, 2, 3, 4, 6, and 8.
Subjects
Youths were referred for possible participation from out-
patients seen at a clinical research center (CRC) located
within an urban, university-based, division of child and
adolescent psychiatry; were respondents to advertising; or
outpatients seen by other mental health providers from
the region.
Outpatients aged 12–17 years, diagnosed with either a
current major depressive disorder (MDD) or other depres-
sive disorder that were also suffering from a comorbid
substance-related disorder were eligible to enroll into this
trial. In addition, eligible patients had to suffer from
depressive symptoms of at least moderate severity (Chil-
dren's Depression Rating Scale-Revised (CDRS-R) total
score ≥ 40) [27]. Additional inclusion and exclusion crite-
ria are shown in Table 1.
Subject diagnosis
Current DSM-IV diagnoses were determined based on the
results of Schedule for Affective Disorders and Schizo-
phrenia for School-Age Children-Present and Lifetime-
Version (KSADS-PL) [28] interview. The KSADS-PL assess-
ment was administered by a child and adolescent psychi-
atrist or by highly trained research assistants. All research
assistants were trained to reach an overall kappa equal to
or greater than 0.85 at the item severity level. In addition,
diagnoses were confirmed by a clinical evaluation by a
child and adolescent psychiatrist. Specification of abuse
disorder (abuse vs. dependence), age of onset of symp-




Patients were randomized to receive either 10 mg of fluox-
etine or matching placebo for the first four weeks of treat-
ment. After four weeks, the dose could be increased to a
maximum dose of 20 mg of fluoxetine or matching pla-
cebo, based upon the treating physician's discretion.
Concomitant medications and therapy
Treatments with other psychotropic medications were not
allowed to be prescribed to the subjects during study
enrollment. While in the study, youths and their families
who were not currently receiving psychotherapy were
offered referrals to community-based resources for sub-
stance use disorders (Alcoholics Anonymous, etc).
Table 1: Inclusion and exclusion criteria
Youths were included in the study only if they met all of the following criteria:
Male and female outpatients.
Youths whose parent/guardian provided signed informed consent.
Youths who provided signed informed assent.
Youths whose parent/guardian agreed to administer study medication daily.
Youths diagnosed with either a current major depressive disorder or depressive disorder and a comorbid substance-related disorder.
Youths suffering from depressive symptoms of at least moderate severity (CDRS-R score ≥ 40).
Youths were excluded from the study for any of the following reasons:
Youths with a clinically-significant general medical or neurological condition.
Youths with clinical evidence to suggest the presence of mental retardation.
Youths for whom treatment with another psychotropic medication would be anticipated while enrolled in the study.
Youths who received treatment with another psychotropic medication within 2 weeks of receiving blinded study medication.
Youths with a history of intolerance, allergy, or non-response to fluoxetine.
Youths who failed 4 weeks of treatment with a non-TCA, non MAOI antidepressant during the current depressive episode.
Youths with a clinically significant abnormal screening laboratory.
Youths who were actively suicidal, or if in the investigator's judgment participation in the study could place the youth at undue risk.
Diagnosis of any of the following DSM-IV defined disorders: bipolar I or II disorder, psychotic disorder (history), obsessive-compulsive disorder 
(current), panic disorder (current), bulimia (current), or anorexia (current).
Females who were pregnant or breastfeeding.
Females who were sexually active and were not using medically accepted means of contraception.
Youths who, in the investigator's opinion, required pharmacological detoxification.Page 3 of 13
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recorded. If youths were receiving chemical dependency
treatment prior to randomization, youths were permitted
to continue these psychosocial interventions while in this
study. However, patients were excluded if there was a sig-
nificant increase in the intensity of a community-based
psychosocial intervention(s) 2 weeks prior to baseline.
Medication adherence
Parents were asked to directly administer the fluoxetine to
the teenagers each morning, rather than have the study
medication self-administered. Adherence to study medi-
cation was assessed by direct inquiry of the parents/
patient, by dosing diaries that were to be returned at each
study visit, and by pill count calculation.
Outcome measures
Data were collected by clinicians and research assistants
who were blinded to treatment group assignment. The
Children's Depression Rating Scale-Revised (CDRS-R)
[27] and the Clinical Global Impressions Scale- Severity
and Improvement (CGI) [29] were obtained at baseline
and the week 1, 2, 3, 4, 6, and 8 study visits. The Beck
Depression Inventory (BDI) [30], the Beck Hopelessness
Scale (BHS) [31], and the Children's Global Assessment
Scale (CGAS) [32] were collected at baseline and week 8
or last week of study participation.
The CDRS-R, a 17-item scale, assesses the severity and
presence of depressive symptoms in children and adoles-
cents. Total scores range from 17 to 113, with a score of 40
usually being indicative of clinical depression [27,33].
The CGI severity and improvement scales assess severity
and improvements of overall psychiatric illness through-
out the duration of the study. CGI Severity (CGI-S) items
are rated from 1 (normal, not ill) to 7 (very, severely ill).
Furthermore, symptom improvement items on the CGI
Improvement (CGI-I) scale are rated from 1 (very much
improved) to 7 (very much worse).
Patient-report of depressive symptomatology was assessed
with the BDI [30]. The 21 items are summed to obtain a
total score that can range from 0 to 63, with scores of 20
or more indicative of moderate to severe depression. The
BHS is a valid and reliable measure designed to assess
three major areas of hopelessness: feelings about the
future, loss of motivation, and expectations [31,34]. The
BHS is composed of 20 true-false questions: nine ques-
tions are keyed false and 11 are keyed true, with one point
being assigned to negative expectations and zero points
being assigned to positive expectations. The responses are
summed to total scores ranging from 0 to 20. Higher
scores are indicative of more hopelessness [35]. Finally,
the CGAS [32] is a clinician-completed rating scale that
provides a single score that reflects a child or adolescent's
overall functional capacity at home, school, and with
peers. Scores range from 1 (indicating a severely impaired




In order to monitor for substance use, urine toxicology
screens were obtained at the screening visit, baseline visit,
and at weeks 2, 4, 8, or at the end of study participation.
Serum ethanol levels were obtained during the screening
process, at the baseline visit and at the end of study. In
addition, a research nurse obtained random urine screens
at weeks 3 or 6 of the study. Urine screens tested for the
presence of amphetamines, opiates, cannabinoids,
cocaine, and phencyclidine. Also, at the study physician's
discretion, a blood ethanol screen was also able to be
obtained at additional study visits if there was a concern
about ongoing ethanol abuse. Youth were considered to
have had a positive substance use screen if either ethanol
and/or any use of the five drugs were detected in blood or
urine samples. At each visit, youths were queried about
between-visit substance use activity.
Safety parameters
Prior to and at each visit during double-blind treatment,
resting blood pressure and pulse were measured. In addi-
tion, weight was obtained at baseline, week 4, and end of
study.
Before patients received study medication, a chemistry
profile, hematology profile, thyroid stimulating hormone
level, and a urinalysis were obtained. In addition, an elec-
trocardiogram was conducted prior to the patient being
prescribed study drug. With the exception of the thyroid
stimulating hormone level, all of these laboratories and
the electrocardiogram were repeated at the end of study
participation. All females had a urine pregnancy test per-
formed at screening and at week 8 or at termination of
study participation.
Adverse event monitoring
Adverse event data were collected by direct query of the
guardians and patients, using the Dosage Record Treat-
ment Emergent Symptom Scale (DOTES) [36] and the
Treatment Emergent Symptoms Scale-Write-In (TESS)
[37]. Any other adverse events that were spontaneously
reported by the patient or guardian were also recorded.
Statistical analyses
Sample size determination
Because no double-blind, placebo-controlled studies of
the efficacy of fluoxetine in pediatric patients with depres-
sion and comorbid substance use disorders had been con-
ducted at the time this study was designed, the fixedPage 4 of 13
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comparable work in adults. A trial of analogous method-
ological design in which 25 adult patients were randomly
assigned to fluoxetine and 26 to placebo [18] found that
fluoxetine was superior to placebo for the treatment of
comorbid major depressive disorder and alcohol depend-
ence. In consideration of the results reported by Cornelius
et al. [18], the original intention of this trial was to have
30 participants randomized to each treatment arm in
order to employ a similarly sized study cohort. However,
this study did not have adequate power to detect a
medium or small effect size as seen in recent antidepres-
sant trials in youths [38,39].
Interim analyses
Due to concerns raised about treatment with fluoxetine
and the development of suicidality in youths prescribed
this agent [23] and in order to assess whether the risk of
exposure to fluoxetine to study participants was justified,
a single interim analysis was conducted after approxi-
mately 50% of patients per treatment group had com-
pleted their participation in the study. Preserving an
overall two-sided Type 1 error rate of .05, Lan-DeMets
[40] group sequential methods with the most conserva-
tive alpha spending function (O'Brien-Fleming) were
used to reject the null hypothesis (efficacy boundary, if
large treatment differences appear before the end of the
study). Whereas repeated testing requires a larger sample
size than the fixed sample size counterparts, one look at
the data maintains a fixed sample size estimate given the
inflation factor is 1.0 [41]. Using results from the interim
analysis, a conditional power (CP) computation for futil-
ity was also conducted, using guidelines adapted from Lan
and Wittes [42]. It was pre-specified that the study would
be stopped for futility at t = 0.5 if CPD(0.5) <= 0.3.
Randomization procedures
Permuted block randomization methods were used to
assure a high degree of balance over time and to provide
adequate non-predictability [39]. Assignment to fluoxet-
ine or placebo was evenly allocated (1:1 treatment alloca-
tion). Randomization was stratified by drug of choice of
the youth (either marijuana or alcohol) and current psy-
chotherapy status (either outpatient, other, or no psycho-
therapy treatment). The randomization sequence was
performed using the pseudo-random number generated
by SAS, version 6.2 (the SAS Institute, Carey, NC).
The Fisher exact test was used to compare rates of study
discontinuation, comorbid psychiatric conditions, con-
comitant psychotherapy, pre-randomization positive
drug toxicology, and dose increases.
Efficacy and other psychometric measure analyses
As in many recent studies of juvenile depression, the pri-
mary measure used to assess the efficacy of fluoxetine was
the CDRS-R [43]. The primary outcome analysis was a
random effects mixed model for repeated measurements
of CDRS-R scores compared between treatment groups
across time. Random-effects estimators included individ-
ual patients; fixed-effects estimators included treatment,
visit, and treatment by visit interaction using a compound
symmetry within-subject variance-covariance matrix.
Degrees of freedom for the F test were computed using the
Satterthwaite formula, a method that provides a more
accurate approximation to the distribution of the F statis-
tic in random effects models than the standard ANOVA
method [44]. The baseline and each post-baseline visit
were included in the model as the dependent variables.
In addition, a CDRS-R "response" rate was prospectively
defined as a ≥ 30% decrease in CDRS-R total score from
week 0 to endpoint (last patient visit, weeks 2 to 8). To
correct for the nonzero minimum score of the CDRS-R, we
used Emslie et al's [16] recommended formula: ([baseline
score - 17] - [endpoint score - 17])/baseline score - 17). In
addition, patients whose endpoint CDRS-R total score
was ≤ 28 were considered "remitted." This definition of
remission has been used in other studies of fluoxetine in
patients with major depression [16,17].
Time to CDRS-R remission was compared between treat-
ment groups using Kaplan-Meier survival analysis. All
other analyses, including mean change in CDRS-R from
baseline to endpoint and weekly analyses, were per-
formed on an intention-to-treat basis.
For analysis of CGI-Improvement, only endpoint values
were compared, since this scale measures total improve-
ment in direct comparison with patient's condition at
baseline. Generalized linear model (GLM) procedures
were used for treatment comparisons in continuous
change scores in the CDRS-R, BHS, BDI, and CGAS from
baseline to endpoint.
Toxicology analyses
The post-randomization drug toxicology screens assessed
at each study visit were compared across treatment groups
using a generalized linear mixed model for discrete out-
comes. Using PROC NLMIXED, the initial model
included treatment, visit (within-subject factor), pre-rand-
omization drug screen status, and all two-way interac-
tions. Non-significant interactions (p ≥ .10) were dropped
from the model.
Adverse events
Treatment-emergent adverse events were compared
between treatment arms. The Fisher exact test was used toPage 5 of 13
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rates in the treatment arms. Changes in blood pressure
and pulse from baseline to endpoint were compared
between fluoxetine and placebo treatment groups using
PROC GLM procedures.
Analyses report on data from all patients enrolled who
received study medication. All tests of hypotheses were
considered statistically significant if the two-sided p value
was less than .05. Four additional tests with the CGI-
Severity, CGI-Improvement, BHS, and CGAS were con-
ducted. The set of 5 tests were considered to be a family
Table 2: Patient demographics
Patient characteristic Total Fluoxetine Placebo P-value*
N = 34 (100%) N = 18 (53%) N = 16 (47%)
Ethnicity, n (%) .75
White 25 (73%) 14 (78%) 11 (19%)
African American 6 (18%) 3 (17%) 3 (69%)
Other 3 (9%) 1 (5%) 2 (12%)
Age (years), mean ± SD 16.46 ± 1.08 16.55 ± 1.11 16.35 ± 1.08 .61
Gender, n (%) .18
Female 5 (15%) 4 (22%) 1 (6%)
Male 29 (85%) 14 (78%) 15 (94%)
Current Depressive Disorder
MDDa 29 (85.3%) 15 (83.3%) 14 (87.5%) 1.0
Other Depressive Disorderb 5 (14.7%) 3 (16.7%) 2 (12.5%) .56
Age at onset of depression, mean ± SD 11.41 ± 2.5 11.9 ± 2.7 10.8 ± 2.1 .19
Length of depression, mean ± SD (weeks) 213.1 ± 153.6 185.0 ± 168.3 244.7 ± 133.4 .26
Current comorbid condition, n (%)
ADHDc 11 (32.4%) 6 (33%) 5 (31.3%) 1.0
Post Traumatic Stress Disorder 2 (5.9%) 1 (5.6%) 1 (6.3%) 1.0
Conduct Disorder 2 (5.9%) 0 (0%) 2 (12.5%) .21
Current SUDd,e
Alcohol 13 (38.2%) 7 (38.9%) 6 (37.5) 1.0
Alcohol Abuse 10 (29.4%) 5 (27.8%) 5 (31.25%) 1.0
Alcohol Dependence 3 (8.8%) 2 (11.1%) 1 (6.25%)
Cannabis 30 (88.2%) 15 (83.3%) 15 (93.8%) .60
Cannabis Abuse 16 (47%) 9 (50.0%) 7 (43.8%) .72
Cannabis Dependence 14 (41.2%) 6 (33.3%) 8 (50.0%)
Polysubstance 1 (2.9%) 0 (0%) 1 (6.3%) .47
Age at onset of SUDe, mean ± SD 13.7 ± 1.2 13.8 ± 1.3 13.7 ± 1.3 .86
Length of SUD, mean ± SD (weeks) 117.4 ± 68.7 116.0 ± 72.4 118.9 ± 66.8 .91
aMajor Depressive Disorder; 2 patients with MDD had a comorbid Dysthymic disorder diagnosis
b4 patients were diagnosed with Dysthymic Disorder, 3 patients had Depression Not Otherwise Specified
cAttention Deficit/Hyperactivity Disorder
dSubstance Use Disorder
e10 patients had more than one substance use disorder
*Fisher's exact test analyses were used to compare percentages; generalized linear model (GLM) procedures were used for comparisons of 
continuous variables between treatment groupsPage 6 of 13
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sive symptoms). Thus the family-wise error rate was set at
0.05. Safety and subgroup analyses were considered sec-
ondary. All analyses were performed with SAS software
version 9.1.2 (SAS Institute, Cary, NC).
Results
The trial was stopped after the interim analysis was per-
formed based on the pre-specified futility stopping rule.
Comparison of the primary outcome via mixture model
analysis crossed the a priori futility boundary for early
stopping with acceptance of the null hypothesis of no
treatment difference in mean change in CDRS-R total
score (estimated treatment difference = 0.19, S.E. = 0.58,
F = 0.14, p = .74).
An identical conclusion was reached using the compari-
son between the proportion of patients with a ≥ 30%
decrease in CDRS-R total score (fluoxetine: 72%; placebo:
81%: p = .69). It was calculated that if the study had con-
tinued to the planned enrollment of 30 patients per treat-
ment arm, the probability of demonstrating a difference
in CDRS-R scores between treatment groups was less than
2% under the alternative hypothesis based on the
observed treatment group differences.
Subject demographics
Eighteen patients were randomly assigned to fluoxetine
treatment and 16 to placebo treatment (Figure 1). There
were no significant between-group differences in baseline
patient demographics (Table 2). Overall, the length of
depressive illness ranged between 20–676 weeks and the
substance use disorder length ranged from 26–312 weeks.
Retrospectively, 26 patients reported that their depressive
symptoms occurred first; 6 subjects reported the depres-
sion and substance use disorder started simultaneously;
one subject reported the onset of the substance use disor-
der prior to the depressive symptoms; and in one subject
this information was not available. Both treatment groups
were balanced in the temporal onset of depression and
substance use disorders (Fisher's Exact test, p = 1.0).
Of the 34 randomized patients (16 placebo, 18 fluoxet-
ine), 25 completed the 8 weeks of treatment (13 placebo,
12 fluoxetine). Two patients experienced adverse events
causing them to discontinue their participation in the
study: one (6%) fluoxetine-treated patient discontinued
due to being hospitalized for suicidal ideation after three
weeks of treatment with 10 mg/day, and 1 (6%) placebo-
treated patient discontinued after one week of study par-
ticipation due to the need for hospitalization for suicidal
ideation with agitation and risk of physical aggression to
others.
There was no significant difference between treatment
groups in the proportion of discontinued patients (p =
.45). Treatment groups were equally balanced for discon-
tinuation due to nonadherence with protocol-related pro-
cedures (fluoxetine: 1 patient [6%]; placebo: 1 patient
[6%]), and patient decision (fluoxetine: 1 patient [6%];
placebo: 1 patient [6%]). Three fluoxetine-treated patients
(17%) and no placebo-treated patient discontinued
because of ineffective treatment (p = .24).
No treatment group differences were found in participa-
tion in psychosocial treatments pre-randomization
(fluoxetine 22% versus placebo 6%; p = .34) or post-ran-
domization (fluoxetine 6% versus placebo 19%; p =
0.32). Four fluoxetine-treated patients (25%) and 4 pla-
cebo-treated patients (22%) were exposed to psychosocial
treatments either at baseline and/or during the trial (p =
.85).
Dosing
Ten of the 15 subjects who were enrolled for a minimum
of 4 weeks and were randomized to receive fluoxetine had
their dose increased to the maximum dose of 20 mg dur-
ing the course of the study. All 14 subjects who were ran-
domized to placebo and completed 4 weeks of treatment
had their "dose" of blinded medication "increased" to 20
mg. The rate of patients who had their dose increased dif-
fered significantly between the two treatment groups (p =
0.042).
Efficacy assessments
Placebo-treated patients experienced a greater mean
reduction in CDRS-R score than fluoxetine-treated
patients at end of study participation (-4.23, 95% confi-
dence interval [CI], -12.95 to 4.49). Although both groups
had a reduction in CDRS-R scores, compared with pla-
cebo, fluoxetine treatment in this trial was not associated
with greater improvement in CDRS-R. More specifically,
in the random effects mixture model for repeated meas-
urements, there was no significant treatment by visit inter-
action (p = .14), indicating no difference between
treatment groups in mean change in CDRS-R score at any
week during the trial. As shown in Figure 2, those subjects
that received placebo showed a greater decrease in CDRS-
R scores from baseline beginning at week 5 in comparison
to those subjects that received fluoxetine. Using recom-
mended methods [45], primary outcome results remained
constant when the extreme CDRS-R score observed (most
severe/least severe) was assumed for these 3 fluoxetine-
treated patients.
Fifty percent of patients in both treatment groups met the
a priori defined criteria for remission (p = 1.0). Further-
more, using survival analyses, there were no significant
differences between treatment groups in time to CDRS-RPage 7 of 13
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Placebo (n=16) 
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0.83).
Other psychometric analyses
Table 3 includes mean psychometric scores at baseline
and end of study. Half of all fluoxetine-treated patients
(50%) were rated much or very much improved (CGI-
Improvement score of 1 or 2) compared with 38% of pla-
cebo-treated patients (p = 0.51). As can be seen in Table 3,
no significant differences between treatment groups in
improvement were found in CGI-severity score, BHS
score, BDI score, and CGAS score. The finding that the
95% confidence interval of the difference between treat-
ment groups in mean change in CGI-Improvement, CGI-
Severity, BHS, BDI, and CGAS scores each span zero con-
firms that the two treatment groups did not separate sig-
nificantly on mean improvements on any scale utilized in
this clinical trial.
Drug toxicology screen analyses
Fourteen of the 16 of subjects in the placebo group and
13/18 subjects in the fluoxetine group had random urine
toxicology tests obtained at either week 3, week 6, or both
time points. No between treatment group differences were
found in pre-randomization rates of positive drug toxicol-
ogy (fluoxetine: 83% versus placebo 75%; p = .68). Post-
randomization rates of any positive drug toxicology at
each study visit are presented in Figure 3. As shown in Fig-
ure 3, there was no significant difference in rates of posi-
tive drug toxicology between treatment groups at any
post- randomization visit (F = 0.22, df = 1, p = 0.65). In
addition, over the course of the trial, no alcohol was
detected in the serum ethanol levels.
Safety assessments
No statistically significant between-group differences in
treatment emergent adverse events were observed during
the 8 weeks of this study (Table 4).
In addition, there were no statistically significant differ-
ences in changes from baseline and end of treatment in
systolic blood pressure, diastolic blood pressure, and
pulse between the treatment groups (all p values > .05).
Furthermore, no statistically significant differences for
changes from baseline and end of study in weight were
found between treatment groups. In addition, there were
no clinically significant blood pressure, pulse, electrocar-
diogram, or laboratory assessments noted during the
course of the trial.
Discussion
In this study, fluoxetine was found not to be superior to
placebo in the acute treatment of depressive symptoms in
depressed adolescents with a concomitant substance-
related disorder. In addition, those patients treated with
fluoxetine did not show a significantly greater decrease in
their substance use in comparison to those patients who
received placebo. However, it should be noted that the
assessment of substance use described in this report was
based on the number of positive drug screens rather than
actual quantities of substances used. Therefore, it is possi-
ble that the amount of drug use significantly diminished
but the frequency of use remained the same.
A key observation was the high placebo response rate seen
in this trial. The baseline characteristics of these youths
suggest that they were substantively symptomatic prior to
receiving treatment under the auspices of this clinical trial.
In prior acute treatment studies of MDD in youths with-
out substance use disorders, fluoxetine was found to be
superior to placebo [15-17]. In those trials, youths had
baseline mean CDRS-R scores ranging from approxi-
mately 55 to 61 in the treatment groups. It is possible that
the more modest depression severity of this cohort con-
tributed to the high placebo response rate. Whether or not
the presence of a substance use disorder influences pla-
cebo response is a question worthy of further study.
Mean change from baseline for fluoxetine- and placebo-tr ted pati nts on the Children's D pr ssion Rating Scale-RevisFigure 2
Mean change from baseline for fluoxetine- and pla-
cebo-treated patients on the Children's Depression 
Rating Scale-Revised. *Random effects regression model 
indicated that there was no significant treatment by visit 
interaction (p = .14).
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cebo on the primary outcome measure, the percentage of
subjects in both treatment groups who were rated much
or very much improved (CGI-Improvement score of 1 or
2), appears to be similar to rates of response that have
been found in previous fluoxetine treatment studies of
depression in youths free of substance use disorders [15-
17]. The discrepancy between CDRS-R score reductions
and CGI-I response rates may have occurred as a result of
the fact that response based on CGI-I ratings reflect overall





Change Baseline Placebob 
Endpoint




CDRS-R 53.0 ± 2.32 34.60 ± 3.22 -18.40 ± 2.94 53.94 ± 2.46 31.31 ± 3.42 -22.63 ± 3.12 -4.23
(-12.95–4.49)
.33 0.98
CGI-S 4.28 ± 0.15 2.88 ± 0.28 -1.39 ± 0.28 4.37 ± 0.16 2.87 ± 0.30 -1.50 ± 0.30 -0.11
(-0.95–0.73)
.71 0.07
CGI-I -- 2.61 ± 0.32 -- -- 2.44 ± 0.34 -- -0.17
(-1.12–0.77)
.79 0.14
BDI 17.20 ± 3.10 7.62 ± 1.96 -9.58 ± 3.29 13.00 ± 3.33 8.12 ± 2.11 -4.88 ± 3.54 4.70
(-5.23–14.63)
.34 0.95
BHS 7.33 ± 1.38 4.07 ± 1.10 -3.27 ± 1.38 7.69 ± 1.49 5.46 ± 1.18 -2.23 ± 1.48 1.04
(-3.12–5.19)
.61 0.26
CGAS 53.06 ± 2.06 69.63 ± 3.62 16.56 ± 3.50 51.21 ± 2.20 65.93 ± 3.87 14.71 ± 3.75 1.85
(-8.67–12.37)
.72 0.13
Values represent mean ± SE from fixed effects parameter estimates. CDRS-R = Children's Depression Rating Scale-Revised; CGI-S = Clinical Global 
Impressions – Severity scale; CGI-I = Clinical Global Impressions – Improvement Scale; BDI = Beck Depression Inventory; BHS=Beck Hopelessness 
Scale; CGAS = Children's Global Assessment of Functioning
aFluoxetine: last observation carried forward: for BDI, n = 15, for BHS, n = 15, for CGAS, n = 16.
bPlacebo: last observation carried forward: for BDI, n = 13, for BHS, n = 13, for CGAS, n = 14.
cDifference in Change shows the difference in average change score of fluoxetine-treated patients in comparison to placebo-treated patients. The 
95% confidence intervals for the differences are shown in parentheses below. If the entire 95% confidence interval is greater than zero, this 
indicates a 95% or greater probability that the mean change associated with fluoxetine treatment is greater than the mean change associated with 
placebo.
dGeneralized linear model (GLM) procedures were used for analysis of continuous baseline and endpoint values; Value for difference in mean 
change between treatment groups, using Type III difference of least square means.








Headache 18 (53%) 10 (56%) 8 (50%) 0.75
Nasal Congestion 13 (38%) 7 (39%) 6 (38%) 0.67
Drowsiness 8 (24%) 6 (33%) 2 (13%) 0.97
Nausea/Vomiting 8 (24%) 5 (28%) 3 (19%) 0.85
Stomach Pain 7 (21%) 2 (11%) 5 (31%) 0.21
Diarrhea 4 (12%) 2 (11%) 2 (13%) 0.65
Dry Mouth 3 (9%) 1 (6%) 2 (13%) 0.45
Syncope/Dizziness 3 (9%) 2 (11%) 1 (6%) 0.86
Insomnia 3 (9%) 1 (6%) 2 (13%) 0.45
*Fisher exact test was used to compare occurrences of adverse 
events across treatment groups.
Percent of patients with positive drug tests who received fluoxetine or placebo for 8 weeksFigure 3
Percent of patients with positive drug tests who 
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whereas the CDRS-R solely considers depressive symp-
tomatology.
In a randomized controlled trial of fluoxetine and CBT in
adolescents with major depression, behavior problems,
and substance use disorders, greater efficacy in combined
fluoxetine and CBT treatment in comparison to placebo
and CBT treatment emerged subsequent to 8 weeks of
study participation into a trial period of 16 weeks [22].
Therefore, the length of the trial described herein, as well
as absence of conjunctive CBT, may have affected our abil-
ity to detect a difference between the two treatment
groups.
Owing to concerns regarding tolerability in a group of
youths who were at risk for ongoing substance abuse, the
dose of fluoxetine used in this study was limited to a max-
imum of 20 mg/day. Although the efficacy of higher doses
of fluoxetine was not examined, it should be noted that
other studies [16,17] found a significant difference
between youth treated with 20 mg of fluoxetine in com-
parison to subjects who received placebo. Furthermore,
when considering the substantive response rate seen in
this trial, it appears that despite the use of a comparatively
limited dose range of fluoxetine, patients were not under-
dosed in this study.
Caution should be taken when interpreting the results of
this study. A key limitation of this study is its small sample
size and resulting low statistical power. Furthermore, the
brevity of this study prevents definitive conclusions about
the safety of fluoxetine treatment in this study population
from being made. Additionally, because this study was
designed to be 8 weeks in length, like other placebo-con-
trolled fluoxetine trials in youths [16,17], whether or not
separation from placebo may have become evident with a
longer treatment duration remains an empiric question.
As noted above, another main limitation is the high pla-
cebo response rate. Other methodological shortcomings
include: 1) the serum ethanol measurements employed in
this study designed were ineffective in detecting alcohol
consumption; and 2) the degree of marijuana abuse was
not quantified as part of the drug screens used in this trial.
It should be noted that serum ethanol screens were used
because of issues pertaining to feasibility. There also were
concerns that more exhaustive testing for substances of
abuse would have likely increased subject burden to a
degree that it would have adversely influenced recruit-
ment.
Another potential limitation is that this study did not spe-
cifically recruit youths suffering with only one specific
substance abuse disorder. Also, despite the fact that
youths with other types of substance-related disorders
might have been eligible for study participation, the
patients studied in this trial primarily suffered from alco-
hol and/or marijuana use disorders.
As mentioned earlier, owing to concerns regarding fluox-
etine tolerability in this particular group of adolescents,
the dose of fluoxetine used in this study was limited to 20
mg/day. Therefore, it is not clear whether or not the study
subjects could have derived more substantive benefits
from higher doses of fluoxetine.
In addition, this study did not exclude youth who met cri-
teria for depression disorders other than MDD. Although
less than 15% of youths had depression disorders other
than MDD, a low proportion of the sample well-balanced
across treatment groups at baseline, it is possible that this
wider range of subject diagnoses may have influenced this
trial's results. However, despite its limitations, this study
demonstrated the feasibility of doing such a trial in this
challenging population.
Conclusion
In this study, short-term treatment with fluoxetine was
not superior to placebo in alleviating depressive symp-
toms or decreasing rates of positive drug screens in adoles-
cents with depression and a substance use disorder.
However, fluoxetine was found to be reasonably well-tol-
erated when compared to placebo. Further research, spe-
cifically secondary analyses of the study outcomes, may
help provide insights into why these findings diverge from
results from previously conducted studies in which fluox-
etine was shown to be superior to placebo in youths with
and without substance use disorders.
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